State Senator Carla Nelson explains how the pharmaceutical industry is reacting to her bill requiring payers to cover all approved biosimilars and reference products.
Why is Minnesota a good place to try a bill of this type, especially since it's the first of its kind in the country?
Nelson: Well, I think Minnesota is a great place, because number 1: we like to be a state of innovation. Whether it be education or in other areas, Minnesota is an innovator. Secondly, we are a hotbed of excellent health care. And I'll give a shout-out to the Mayo Clinic, which is in my district in Rochester. We have a number of gold standard health care providers in our state. We also are a state known for medical innovation, and so a medical ally comes to mind. So, Minnesota is the place to do this. And I'm very proud of the fact that our first biosimilar bill actually passed before we even had 1 biosimilar in our nation. And the point is, we should be on the cutting edge of this and Minnesota can lead. It will be great for our citizens and it will also be great for those [companies] who will continue to [develop] those biosimilars that will have the same outcomes, but at a much lower cost.
What are the politics involved here and are you feeling any pushback from the payer or manufacturer community?
Nelson: There's always pushback to change, and the key is really listening to those objections—really trying to sort out which ones are objections that matter, [such as] how is it affecting the patient? How is it affecting the doctor-patient relationship? How is it affecting the cost and the choice? So, those are the things that really come to the front. I'm very pleased with the language we have in [the bill, addressing] wholesale cost and covering biosimilars that are at a lower cost. I think those are 2 really key pieces that are going to help drive this to fruition and actually incentivize more biosimilars and get lower-cost of drugs to our patients on time without needing to go through the delay of prior authorization. And I think our medical providers will appreciate as well that these things are covered on the formulary, so they don't have to go through the cycle of paperwork for things like prior authorizations.
To read more about SF 990, click here.
To hear about this bill from State Representative Jennifer Schultz, co-author of SF 990, click here.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.